StockWatch
·

GLENMARK PHARMACEUTICALS LTD. Q2 FY27 Results

GLENMARKQ2 FY27 Results
Filing
Result:Weak· Market: Up#Base effect#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue4.2K3.5%31.3%
Total Income4.2K4.1%32.0%
Expenditure3.6K5.4%6.9%
PBT338.2947.4%65.0%
Net Profit263.8345.4%56.8%
OPM11.78%8.25pp4.33pp
NPM6.21%5.61pp3.56pp
EPS9.3545.4%56.8%
View full financials

Revenue (-31% YoY) and adjusted PAT (-57% YoY) both declined sharply with OPM compressing from 16.1% to 11.8%, and the decline is exaggerated by a high prior-year base that included one-off AbbVie licensing income, so there's no beat/miss data available but the core business clearly weakened.

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue4.2K3.5%31.3%
Total Income4.2K4.1%32.0%
Expenditure3.6K5.4%6.9%
PBT338.2947.4%65.0%
Net Profit263.8345.4%56.8%
OPM11.78%8.25pp4.33pp
NPM6.21%5.61pp3.56pp
EPS9.3545.4%56.8%
View full financials

Detailed report is being prepared.

Informational and educational content only. Not investment advice.